Drug Profile

Apaziquone - Assertio Therapeutics

Alternative Names: EO 9; EOquin; Neoquin; NOR-701; NSC 382459; Qapzola

Latest Information Update: 22 Jun 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Spectrum Pharmaceuticals
Developer Handok Inc; Nippon Kayaku; Spectrum Pharmaceuticals
Class Aziridines; Cytostatic antibiotics; Indolequinones; Small molecules
Mechanism of Action Alkylating agents; DNA synthesis inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Bladder cancer; Leucoplakia

Most Recent Events

16 Jun 2026 Assertio Therapeutics has been acquired by Zydus Lifesciences
06 Oct 2021 Discontinued - Phase-I/II for Leucoplakia in India (Topical)
06 Oct 2021 Discontinued - Phase-II for Bladder cancer (Adjuvant therapy) in Japan (Intravesicular)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com